Blog
Drug Target Encyclopedia Series (18) —GPRC5D
Release Time：
2025-12-05 14:16
GPRC5D (G protein–coupled receptor, class C, group 5, member D) is an orphan receptor highly expressed in multiple myeloma (MM) cells but minimally in normal tissues, making it a promising immuno-oncology target for novel therapies.
GPRC5D is implicated in:
• Multiple Myeloma (relapsed/refractory MM)
• Extramedullary plasmacytomas
• Bone marrow–associated malignancies
Targeting GPRC5D in therapy:
- CAR-T cell therapy – Engineered T cells show strong anti-myeloma activity.
- Bispecific T-cell engagers (BiTEs) – Redirect T cells to attack GPRC5D+ plasma cells.
- Antibody-drug conjugates (ADCs) – Selective cytotoxic payload delivery to myeloma cells.
Key challenges include:
• Understanding resistance mechanisms in GPRC5D-targeted therapies
• Managing on-target/off-tumor effects (e.g., keratinized tissue expression)
• Need for combinational strategies with BCMA-targeted therapies
🔬 Ongoing research is rapidly advancing GPRC5D-targeted immunotherapies, with encouraging results in clinical trials for relapsed or refractory multiple myeloma.
Need GPRC5D
Fill out the form below, or visit the link: to browse the complete list of available in-stock products.
E-mail：support@levostar.com
USA
16192 Coastal Hwy，Lewes, DE 19958
TEL：619-537-9202
China
A3-502 No.328, Xinghu Street, Suzhou Industrial Park, Suzhou, Jiangsu, China 215123
TEL：0512-62888898